IP Library Granted Patent US 7,799,954
Granted Patent B2
US 7,799,954 · App. 11/939,909 · Granted Sep 21, 2010

Dicarbonyl derivatives and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,799,954
App. No.
11/939,909
Granted
Sep 21, 2010
Kind
B2
Abstract

Derivatives of dicarbonyl compounds having antitumor and antibiotic activity which can be used as anticancer agents.

Claims (64)

1. A compound or pharmaceutically acceptable salt thereof having the formula (I)

wherein

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently a hydrogen atom or an alkyl, alkenyl, alkynyl, or aryl comprising 1 to 30 carbon atoms and which is unsubstituted or substituted by at least one of hydroxy, cyano, mercapto, halogen, —OR 7 , SR 7 , —NR 7 R 8 , —CONR 7 R 8 , or —OCONR 7 R 8 , wherein

R 7 and R 8 are a hydrogen atom; an alkyl, alkenyl, or alkynyl comprising 1 to 20 carbon atoms; a cyclic or heterocyclic group comprising 5 or 6 ring atoms of which from 0 to 3 are nitrogen and/or oxygen and/or sulphur hetero-atoms, said cyclic or heterocyclic group being unsubstituted or substituted by at least one of hydroxy, cyano, mercapto, halogen, or an alkyl group comprising 1 to 6 carbon atoms; and X and Y are respectively O, NR 7 or S, wherein when X and Y are O, and if R 2 , R 4 are hydrogen, R 1 -R 3 or both R 1 -R 3 and R 5 -R 6 form a cyclic or an acyclic alkenyl; when X and Y are O, and if R 2 , R 4 form a single bond, R 1 is

wherein Ar is an aryl or heteroaryl.

2. The compound of claim 1 , wherein X and Y are O, and R 6 is —NR 7 R 8 .

3. The compound of claim 1 , wherein X and Y are O.

4. The compound of claim 1 , wherein the compound has the following formula:

5. The compound of claim 4 , wherein R 7 and R 8 are C 1 -C 10 alkyl and C 6 -C 10 aryl, respectively.

6. The compound of claim 1 , wherein the compound has the following formula:

7. The compound of claim 6 , wherein R 7 and R 8 are C 1 -C 10 alkyl and C 6 -C 10 aryl, respectively.

8. The compound of claim 7 , wherein X is H, 3-OMe, 4-OMe, or 3,4-di-OMe.

9. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

11. The pharmaceutical composition of claim 10 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

12. The pharmaceutical composition of claim 10 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

13. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral, parenteral, intravenous, and combinations thereof.

15. The pharmaceutical composition of claim 14 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

16. The pharmaceutical composition of claim 14 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

17. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral, parenteral, intravenous, and combinations thereof.

19. The pharmaceutical composition of claim 18 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

20. The pharmaceutical composition of claim 18 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

21. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition of claim 21 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

23. The pharmaceutical composition of claim 22 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

24. The pharmaceutical composition of claim 22 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

25. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

26. The pharmaceutical composition of claim 25 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

27. The pharmaceutical composition of claim 26 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

28. The pharmaceutical composition of claim 26 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

29. A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.

30. The pharmaceutical composition of claim 29 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

31. The pharmaceutical composition of claim 30 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

32. The pharmaceutical composition of claim 30 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, and tonicity adjusting agents.

33. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.

34. The pharmaceutical composition of claim 33 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral, and parenteral administration.

35. The pharmaceutical composition of claim 34 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

36. The pharmaceutical composition of claim 34 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

37. A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable carrier.

38. The pharmaceutical composition of claim 37 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

39. The pharmaceutical composition of claim 38 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

40. The pharmaceutical composition of claim 38 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

41. The compound of claim 8 , wherein X is H.

42. The compound of claim 8 wherein X is 3-OMe.

43. The compound of claim 8 wherein X is 4-OMe.

44. The compound of claim 8 wherein X is 3, 4-di-OMe.

45. A pharmaceutical composition comprising the compound of claim 41 and a pharmaceutically acceptable carrier.

46. The pharmaceutical composition of claim 45 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

47. The pharmaceutical composition of claim 46 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

48. The pharmaceutical composition of claim 46 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

49. A pharmaceutical composition comprising the compound of claim 42 and a pharmaceutically acceptable carrier.

50. The pharmaceutical composition of claim 49 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

51. The pharmaceutical composition of claim 50 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

52. The pharmaceutical composition of claim 50 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

53. A pharmaceutical composition comprising the compound of claim 43 and a pharmaceutically acceptable carrier.

54. The pharmaceutical composition of claim 53 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

55. The pharmaceutical composition of claim 54 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

56. The pharmaceutical composition of claim 54 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

57. A pharmaceutical composition comprising the compound of claim 44 and a pharmaceutically acceptable carrier.

58. The pharmaceutical composition of claim 57 , wherein the composition is suitable for delivery via routes of administration selected from the group consisting of oral and parenteral administration.

59. The pharmaceutical composition of claim 58 , wherein said composition is suitable for oral delivery and further comprises one or more ingredients selected from the group consisting of a diluent, an edible carrier, a binder, an excipient, a disintegrating agent, a lubricant, a glidant, and a sweetening agent.

60. The pharmaceutical composition of claim 58 , wherein said composition is suitable for parenteral delivery and comprises one or more ingredients selected from the group consisting of a sterile diluent, antimicrobial agents, antioxidants, buffers, tonicity and adjusting agents.

Assignments (5)
CHANGE OF NAME Recorded Oct 27, 2016
From: NANTBIO, INC.
To: NANTBIOSCIENCE, INC.
Reel/Frame 040500/0796 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2014
From: NANT HOLDINGS IP, LLC
To: NANTBIO, INC.
Reel/Frame 032635/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: ABRAXIS BIOSCIENCE, INC.; ABRAXIS BIOSCIENCE, LLC
To: CALIFORNIA CAPITAL EQUITY, LLC
Reel/Frame 031229/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: CALIFORNIA CAPITAL EQUITY, LLC
To: NANT HOLDINGS IP, LLC
Reel/Frame 031230/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2008
From: TAO, CHUNLIN; WANG, QINWEI; TRIEU, VUONG; DESAI, NEIL; SOON-SHIONG, PATRICK
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 020424/0737 →